3 results
Approved WMOWill not start
In Part 1 of the study, a fixed dose of ABBV-3067 (potentiator) will be co-administered with ABBV-2222 (corrector) in a dose range-finding manner to enable a dose selection for ABBV-2222 for Part 2 and future combination studies. In addition, ABBV-…
Approved WMOPending
The primary objective is to demonstrate a difference in the proportion of patients with progressed/worsened disease state in patients receiving FX06 compared to patients receiving placebo until day 28.Assessment and treatment comparison of the…
Approved WMOCompleted
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.